nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentoxifylline—Fenethylline—Methamphetamine—obesity	0.508	1	CrCrCtD
Pentoxifylline—CYP1A2—Phentermine—obesity	0.0447	0.292	CbGbCtD
Pentoxifylline—CYP1A2—Phenylpropanolamine—obesity	0.0427	0.278	CbGbCtD
Pentoxifylline—CYP1A2—Bupropion—obesity	0.038	0.248	CbGbCtD
Pentoxifylline—CYP1A2—Cimetidine—obesity	0.0279	0.182	CbGbCtD
Pentoxifylline—NT5E—brown adipose tissue—obesity	0.0119	0.244	CbGeAlD
Pentoxifylline—NT5E—respiratory system—obesity	0.00238	0.0487	CbGeAlD
Pentoxifylline—NT5E—cardiovascular system—obesity	0.00182	0.0373	CbGeAlD
Pentoxifylline—NT5E—pituitary gland—obesity	0.00161	0.0331	CbGeAlD
Pentoxifylline—NT5E—adipose tissue—obesity	0.00161	0.0329	CbGeAlD
Pentoxifylline—PDE5A—respiratory system—obesity	0.00155	0.0316	CbGeAlD
Pentoxifylline—NT5E—adrenal gland—obesity	0.00144	0.0295	CbGeAlD
Pentoxifylline—ADORA2B—pituitary gland—obesity	0.00138	0.0283	CbGeAlD
Pentoxifylline—Caffeine—PIK3CD—obesity	0.00138	0.305	CrCbGaD
Pentoxifylline—Caffeine—PIK3CB—obesity	0.00138	0.305	CrCbGaD
Pentoxifylline—ADORA2B—adipose tissue—obesity	0.00138	0.0282	CbGeAlD
Pentoxifylline—ADORA2A—cardiovascular system—obesity	0.0013	0.0266	CbGeAlD
Pentoxifylline—NT5E—endocrine gland—obesity	0.00125	0.0256	CbGeAlD
Pentoxifylline—PDE4A—adipose tissue—obesity	0.00123	0.0251	CbGeAlD
Pentoxifylline—PDE5A—cardiovascular system—obesity	0.00118	0.0242	CbGeAlD
Pentoxifylline—PDE4B—islet of Langerhans—obesity	0.00115	0.0235	CbGeAlD
Pentoxifylline—NT5E—liver—obesity	0.00113	0.0231	CbGeAlD
Pentoxifylline—ADORA1—cardiovascular system—obesity	0.00112	0.023	CbGeAlD
Pentoxifylline—PDE4A—adrenal gland—obesity	0.0011	0.0225	CbGeAlD
Pentoxifylline—PDE4B—respiratory system—obesity	0.00108	0.0222	CbGeAlD
Pentoxifylline—Caffeine—PIK3CA—obesity	0.00107	0.236	CrCbGaD
Pentoxifylline—PDE5A—adipose tissue—obesity	0.00104	0.0214	CbGeAlD
Pentoxifylline—ADORA2A—adrenal gland—obesity	0.00103	0.021	CbGeAlD
Pentoxifylline—ADORA1—adipose tissue—obesity	0.000989	0.0203	CbGeAlD
Pentoxifylline—PDE5A—digestive system—obesity	0.000983	0.0201	CbGeAlD
Pentoxifylline—PDE5A—adrenal gland—obesity	0.000936	0.0192	CbGeAlD
Pentoxifylline—ADORA2A—endocrine gland—obesity	0.000891	0.0182	CbGeAlD
Pentoxifylline—PDE5A—endocrine gland—obesity	0.000812	0.0166	CbGeAlD
Pentoxifylline—ADORA2A—liver—obesity	0.000804	0.0165	CbGeAlD
Pentoxifylline—ADORA1—endocrine gland—obesity	0.00077	0.0158	CbGeAlD
Pentoxifylline—PDE4B—pituitary gland—obesity	0.000735	0.015	CbGeAlD
Pentoxifylline—PDE4B—adipose tissue—obesity	0.000732	0.015	CbGeAlD
Pentoxifylline—CYP1A2—respiratory system—obesity	0.000666	0.0136	CbGeAlD
Pentoxifylline—PDE4B—adrenal gland—obesity	0.000657	0.0134	CbGeAlD
Pentoxifylline—PDE4B—endocrine gland—obesity	0.000569	0.0117	CbGeAlD
Pentoxifylline—PDE4B—liver—obesity	0.000513	0.0105	CbGeAlD
Pentoxifylline—Theobromine—CYP2E1—obesity	0.000463	0.102	CrCbGaD
Pentoxifylline—CYP1A2—digestive system—obesity	0.000423	0.00866	CbGeAlD
Pentoxifylline—CYP1A2—endocrine gland—obesity	0.00035	0.00716	CbGeAlD
Pentoxifylline—CYP1A2—liver—obesity	0.000315	0.00645	CbGeAlD
Pentoxifylline—Conjunctivitis—Bupropion—obesity	0.000292	0.00193	CcSEcCtD
Pentoxifylline—Ear pain—Topiramate—obesity	0.000291	0.00192	CcSEcCtD
Pentoxifylline—Immune system disorder—Orlistat—obesity	0.000288	0.00191	CcSEcCtD
Pentoxifylline—Sweating—Bupropion—obesity	0.000288	0.0019	CcSEcCtD
Pentoxifylline—Sleep disorder—Topiramate—obesity	0.000287	0.0019	CcSEcCtD
Pentoxifylline—Dizziness—Diethylpropion—obesity	0.000285	0.00189	CcSEcCtD
Pentoxifylline—Epistaxis—Bupropion—obesity	0.000283	0.00187	CcSEcCtD
Pentoxifylline—Diarrhoea—Cimetidine—obesity	0.000281	0.00186	CcSEcCtD
Pentoxifylline—Immune system disorder—Sibutramine—obesity	0.000279	0.00185	CcSEcCtD
Pentoxifylline—Vascular purpura—Topiramate—obesity	0.000277	0.00184	CcSEcCtD
Pentoxifylline—Arrhythmia—Sibutramine—obesity	0.000276	0.00183	CcSEcCtD
Pentoxifylline—Vomiting—Diethylpropion—obesity	0.000275	0.00182	CcSEcCtD
Pentoxifylline—Flatulence—Orlistat—obesity	0.000274	0.00181	CcSEcCtD
Pentoxifylline—Nasal congestion—Topiramate—obesity	0.000272	0.0018	CcSEcCtD
Pentoxifylline—Rash—Diethylpropion—obesity	0.000272	0.0018	CcSEcCtD
Pentoxifylline—Dysgeusia—Orlistat—obesity	0.000272	0.0018	CcSEcCtD
Pentoxifylline—Dermatitis—Diethylpropion—obesity	0.000272	0.0018	CcSEcCtD
Pentoxifylline—Dizziness—Cimetidine—obesity	0.000272	0.0018	CcSEcCtD
Pentoxifylline—Haemoglobin—Bupropion—obesity	0.000271	0.00179	CcSEcCtD
Pentoxifylline—Headache—Diethylpropion—obesity	0.00027	0.00179	CcSEcCtD
Pentoxifylline—Haemorrhage—Bupropion—obesity	0.000269	0.00178	CcSEcCtD
Pentoxifylline—Hepatitis—Bupropion—obesity	0.000269	0.00178	CcSEcCtD
Pentoxifylline—Back pain—Orlistat—obesity	0.000269	0.00178	CcSEcCtD
Pentoxifylline—Muscle spasms—Orlistat—obesity	0.000267	0.00177	CcSEcCtD
Pentoxifylline—Flatulence—Sibutramine—obesity	0.000265	0.00175	CcSEcCtD
Pentoxifylline—Tension—Sibutramine—obesity	0.000264	0.00175	CcSEcCtD
Pentoxifylline—Dysgeusia—Sibutramine—obesity	0.000263	0.00174	CcSEcCtD
Pentoxifylline—Vision blurred—Orlistat—obesity	0.000262	0.00173	CcSEcCtD
Pentoxifylline—Nervousness—Sibutramine—obesity	0.000261	0.00173	CcSEcCtD
Pentoxifylline—Vomiting—Cimetidine—obesity	0.000261	0.00173	CcSEcCtD
Pentoxifylline—Thirst—Topiramate—obesity	0.000261	0.00173	CcSEcCtD
Pentoxifylline—Back pain—Sibutramine—obesity	0.00026	0.00172	CcSEcCtD
Pentoxifylline—Rash—Cimetidine—obesity	0.000259	0.00172	CcSEcCtD
Pentoxifylline—Dermatitis—Cimetidine—obesity	0.000259	0.00171	CcSEcCtD
Pentoxifylline—Muscle spasms—Sibutramine—obesity	0.000259	0.00171	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Orlistat—obesity	0.000258	0.00171	CcSEcCtD
Pentoxifylline—Headache—Cimetidine—obesity	0.000257	0.0017	CcSEcCtD
Pentoxifylline—Purpura—Topiramate—obesity	0.000257	0.0017	CcSEcCtD
Pentoxifylline—Nausea—Diethylpropion—obesity	0.000256	0.0017	CcSEcCtD
Pentoxifylline—Angioedema—Orlistat—obesity	0.000254	0.00168	CcSEcCtD
Pentoxifylline—Vision blurred—Sibutramine—obesity	0.000253	0.00168	CcSEcCtD
Pentoxifylline—Tremor—Sibutramine—obesity	0.000252	0.00167	CcSEcCtD
Pentoxifylline—Malaise—Orlistat—obesity	0.000251	0.00166	CcSEcCtD
Pentoxifylline—Flushing—Bupropion—obesity	0.00025	0.00166	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Sibutramine—obesity	0.00025	0.00165	CcSEcCtD
Pentoxifylline—Anaemia—Sibutramine—obesity	0.000249	0.00165	CcSEcCtD
Pentoxifylline—Agitation—Sibutramine—obesity	0.000247	0.00164	CcSEcCtD
Pentoxifylline—Angioedema—Sibutramine—obesity	0.000246	0.00163	CcSEcCtD
Pentoxifylline—Palpitations—Orlistat—obesity	0.000246	0.00163	CcSEcCtD
Pentoxifylline—Nausea—Cimetidine—obesity	0.000244	0.00162	CcSEcCtD
Pentoxifylline—Immune system disorder—Bupropion—obesity	0.000243	0.00161	CcSEcCtD
Pentoxifylline—Malaise—Sibutramine—obesity	0.000243	0.00161	CcSEcCtD
Pentoxifylline—Convulsion—Orlistat—obesity	0.000241	0.00159	CcSEcCtD
Pentoxifylline—Leukopenia—Sibutramine—obesity	0.000241	0.00159	CcSEcCtD
Pentoxifylline—Arrhythmia—Bupropion—obesity	0.000241	0.00159	CcSEcCtD
Pentoxifylline—Caffeine—CYP2E1—obesity	0.000238	0.0525	CrCbGaD
Pentoxifylline—Palpitations—Sibutramine—obesity	0.000238	0.00157	CcSEcCtD
Pentoxifylline—Chest pain—Orlistat—obesity	0.000237	0.00157	CcSEcCtD
Pentoxifylline—Myalgia—Orlistat—obesity	0.000237	0.00157	CcSEcCtD
Pentoxifylline—Anxiety—Orlistat—obesity	0.000236	0.00156	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	0.000235	0.00156	CcSEcCtD
Pentoxifylline—Discomfort—Orlistat—obesity	0.000234	0.00155	CcSEcCtD
Pentoxifylline—Convulsion—Sibutramine—obesity	0.000233	0.00154	CcSEcCtD
Pentoxifylline—Hypertension—Sibutramine—obesity	0.000232	0.00154	CcSEcCtD
Pentoxifylline—Dry mouth—Orlistat—obesity	0.000231	0.00153	CcSEcCtD
Pentoxifylline—Flatulence—Bupropion—obesity	0.000231	0.00153	CcSEcCtD
Pentoxifylline—Tension—Bupropion—obesity	0.00023	0.00152	CcSEcCtD
Pentoxifylline—Dysgeusia—Bupropion—obesity	0.00023	0.00152	CcSEcCtD
Pentoxifylline—Myalgia—Sibutramine—obesity	0.000229	0.00152	CcSEcCtD
Pentoxifylline—Chest pain—Sibutramine—obesity	0.000229	0.00152	CcSEcCtD
Pentoxifylline—Anxiety—Sibutramine—obesity	0.000228	0.00151	CcSEcCtD
Pentoxifylline—Nervousness—Bupropion—obesity	0.000228	0.00151	CcSEcCtD
Pentoxifylline—Oedema—Orlistat—obesity	0.000227	0.0015	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Orlistat—obesity	0.000227	0.0015	CcSEcCtD
Pentoxifylline—Back pain—Bupropion—obesity	0.000227	0.0015	CcSEcCtD
Pentoxifylline—Discomfort—Sibutramine—obesity	0.000226	0.0015	CcSEcCtD
Pentoxifylline—Muscle spasms—Bupropion—obesity	0.000225	0.00149	CcSEcCtD
Pentoxifylline—Infection—Orlistat—obesity	0.000225	0.00149	CcSEcCtD
Pentoxifylline—Dry mouth—Sibutramine—obesity	0.000224	0.00148	CcSEcCtD
Pentoxifylline—Confusional state—Sibutramine—obesity	0.000221	0.00147	CcSEcCtD
Pentoxifylline—Vision blurred—Bupropion—obesity	0.000221	0.00146	CcSEcCtD
Pentoxifylline—Skin disorder—Orlistat—obesity	0.00022	0.00146	CcSEcCtD
Pentoxifylline—Tremor—Bupropion—obesity	0.00022	0.00145	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Sibutramine—obesity	0.000219	0.00145	CcSEcCtD
Pentoxifylline—Oedema—Sibutramine—obesity	0.000219	0.00145	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Orlistat—obesity	0.000219	0.00145	CcSEcCtD
Pentoxifylline—Infection—Sibutramine—obesity	0.000218	0.00144	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Bupropion—obesity	0.000218	0.00144	CcSEcCtD
Pentoxifylline—Anaemia—Bupropion—obesity	0.000217	0.00143	CcSEcCtD
Pentoxifylline—Shock—Sibutramine—obesity	0.000216	0.00143	CcSEcCtD
Pentoxifylline—Abdominal distension—Topiramate—obesity	0.000216	0.00143	CcSEcCtD
Pentoxifylline—Agitation—Bupropion—obesity	0.000215	0.00143	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Sibutramine—obesity	0.000215	0.00142	CcSEcCtD
Pentoxifylline—Angioedema—Bupropion—obesity	0.000214	0.00142	CcSEcCtD
Pentoxifylline—Tachycardia—Sibutramine—obesity	0.000214	0.00142	CcSEcCtD
Pentoxifylline—Skin disorder—Sibutramine—obesity	0.000213	0.00141	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Sibutramine—obesity	0.000212	0.0014	CcSEcCtD
Pentoxifylline—Malaise—Bupropion—obesity	0.000211	0.0014	CcSEcCtD
Pentoxifylline—Leukopenia—Bupropion—obesity	0.00021	0.00139	CcSEcCtD
Pentoxifylline—Anorexia—Sibutramine—obesity	0.000209	0.00139	CcSEcCtD
Pentoxifylline—Angina pectoris—Topiramate—obesity	0.000209	0.00138	CcSEcCtD
Pentoxifylline—Palpitations—Bupropion—obesity	0.000207	0.00137	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Orlistat—obesity	0.000207	0.00137	CcSEcCtD
Pentoxifylline—Abdominal discomfort—Topiramate—obesity	0.000206	0.00136	CcSEcCtD
Pentoxifylline—Insomnia—Orlistat—obesity	0.000205	0.00136	CcSEcCtD
Pentoxifylline—Hypotension—Sibutramine—obesity	0.000205	0.00136	CcSEcCtD
Pentoxifylline—Pancytopenia—Topiramate—obesity	0.000204	0.00135	CcSEcCtD
Pentoxifylline—Convulsion—Bupropion—obesity	0.000203	0.00135	CcSEcCtD
Pentoxifylline—Hypertension—Bupropion—obesity	0.000202	0.00134	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Sibutramine—obesity	0.0002	0.00132	CcSEcCtD
Pentoxifylline—Dyspepsia—Orlistat—obesity	0.0002	0.00132	CcSEcCtD
Pentoxifylline—Chest pain—Bupropion—obesity	0.0002	0.00132	CcSEcCtD
Pentoxifylline—Myalgia—Bupropion—obesity	0.0002	0.00132	CcSEcCtD
Pentoxifylline—Anxiety—Bupropion—obesity	0.000199	0.00132	CcSEcCtD
Pentoxifylline—Insomnia—Sibutramine—obesity	0.000199	0.00131	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	0.000198	0.00131	CcSEcCtD
Pentoxifylline—Discomfort—Bupropion—obesity	0.000197	0.00131	CcSEcCtD
Pentoxifylline—Decreased appetite—Orlistat—obesity	0.000197	0.00131	CcSEcCtD
Pentoxifylline—Dyspnoea—Sibutramine—obesity	0.000196	0.0013	CcSEcCtD
Pentoxifylline—Dry mouth—Bupropion—obesity	0.000195	0.00129	CcSEcCtD
Pentoxifylline—Somnolence—Sibutramine—obesity	0.000195	0.00129	CcSEcCtD
Pentoxifylline—Dyspepsia—Sibutramine—obesity	0.000193	0.00128	CcSEcCtD
Pentoxifylline—Confusional state—Bupropion—obesity	0.000193	0.00128	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Bupropion—obesity	0.000191	0.00127	CcSEcCtD
Pentoxifylline—Oedema—Bupropion—obesity	0.000191	0.00127	CcSEcCtD
Pentoxifylline—Infestation NOS—Topiramate—obesity	0.000191	0.00127	CcSEcCtD
Pentoxifylline—Infestation—Topiramate—obesity	0.000191	0.00127	CcSEcCtD
Pentoxifylline—Decreased appetite—Sibutramine—obesity	0.000191	0.00126	CcSEcCtD
Pentoxifylline—Infection—Bupropion—obesity	0.00019	0.00126	CcSEcCtD
Pentoxifylline—Shock—Bupropion—obesity	0.000188	0.00125	CcSEcCtD
Pentoxifylline—Constipation—Sibutramine—obesity	0.000188	0.00124	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Bupropion—obesity	0.000187	0.00124	CcSEcCtD
Pentoxifylline—Feeling abnormal—Orlistat—obesity	0.000187	0.00124	CcSEcCtD
Pentoxifylline—Tachycardia—Bupropion—obesity	0.000187	0.00124	CcSEcCtD
Pentoxifylline—Skin disorder—Bupropion—obesity	0.000186	0.00123	CcSEcCtD
Pentoxifylline—Conjunctivitis—Topiramate—obesity	0.000186	0.00123	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Orlistat—obesity	0.000185	0.00123	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Bupropion—obesity	0.000185	0.00122	CcSEcCtD
Pentoxifylline—Anorexia—Bupropion—obesity	0.000182	0.00121	CcSEcCtD
Pentoxifylline—Feeling abnormal—Sibutramine—obesity	0.000181	0.0012	CcSEcCtD
Pentoxifylline—Epistaxis—Topiramate—obesity	0.00018	0.00119	CcSEcCtD
Pentoxifylline—Urticaria—Orlistat—obesity	0.00018	0.00119	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Sibutramine—obesity	0.000179	0.00119	CcSEcCtD
Pentoxifylline—Abdominal pain—Orlistat—obesity	0.000179	0.00119	CcSEcCtD
Pentoxifylline—Body temperature increased—Orlistat—obesity	0.000179	0.00119	CcSEcCtD
Pentoxifylline—Hypotension—Bupropion—obesity	0.000179	0.00118	CcSEcCtD
Pentoxifylline—Urticaria—Sibutramine—obesity	0.000174	0.00115	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Bupropion—obesity	0.000174	0.00115	CcSEcCtD
Pentoxifylline—Abdominal pain—Sibutramine—obesity	0.000174	0.00115	CcSEcCtD
Pentoxifylline—Body temperature increased—Sibutramine—obesity	0.000174	0.00115	CcSEcCtD
Pentoxifylline—Insomnia—Bupropion—obesity	0.000173	0.00115	CcSEcCtD
Pentoxifylline—Haemoglobin—Topiramate—obesity	0.000172	0.00114	CcSEcCtD
Pentoxifylline—Haemorrhage—Topiramate—obesity	0.000172	0.00114	CcSEcCtD
Pentoxifylline—Hepatitis—Topiramate—obesity	0.000172	0.00114	CcSEcCtD
Pentoxifylline—Dyspnoea—Bupropion—obesity	0.000171	0.00113	CcSEcCtD
Pentoxifylline—Somnolence—Bupropion—obesity	0.00017	0.00113	CcSEcCtD
Pentoxifylline—Dyspepsia—Bupropion—obesity	0.000168	0.00112	CcSEcCtD
Pentoxifylline—Hypersensitivity—Orlistat—obesity	0.000167	0.00111	CcSEcCtD
Pentoxifylline—Decreased appetite—Bupropion—obesity	0.000166	0.0011	CcSEcCtD
Pentoxifylline—Constipation—Bupropion—obesity	0.000164	0.00108	CcSEcCtD
Pentoxifylline—Asthenia—Orlistat—obesity	0.000163	0.00108	CcSEcCtD
Pentoxifylline—Hypersensitivity—Sibutramine—obesity	0.000162	0.00107	CcSEcCtD
Pentoxifylline—Pruritus—Orlistat—obesity	0.00016	0.00106	CcSEcCtD
Pentoxifylline—Flushing—Topiramate—obesity	0.000159	0.00105	CcSEcCtD
Pentoxifylline—Feeling abnormal—Bupropion—obesity	0.000158	0.00104	CcSEcCtD
Pentoxifylline—Asthenia—Sibutramine—obesity	0.000157	0.00104	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Bupropion—obesity	0.000156	0.00104	CcSEcCtD
Pentoxifylline—Pruritus—Sibutramine—obesity	0.000155	0.00103	CcSEcCtD
Pentoxifylline—Diarrhoea—Orlistat—obesity	0.000155	0.00103	CcSEcCtD
Pentoxifylline—Immune system disorder—Topiramate—obesity	0.000155	0.00103	CcSEcCtD
Pentoxifylline—Urticaria—Bupropion—obesity	0.000152	0.00101	CcSEcCtD
Pentoxifylline—Abdominal pain—Bupropion—obesity	0.000151	0.001	CcSEcCtD
Pentoxifylline—Body temperature increased—Bupropion—obesity	0.000151	0.001	CcSEcCtD
Pentoxifylline—Diarrhoea—Sibutramine—obesity	0.00015	0.000994	CcSEcCtD
Pentoxifylline—Dizziness—Orlistat—obesity	0.00015	0.000993	CcSEcCtD
Pentoxifylline—Erythema—Topiramate—obesity	0.000149	0.000989	CcSEcCtD
Pentoxifylline—Flatulence—Topiramate—obesity	0.000147	0.000975	CcSEcCtD
Pentoxifylline—Tension—Topiramate—obesity	0.000147	0.000971	CcSEcCtD
Pentoxifylline—Dysgeusia—Topiramate—obesity	0.000146	0.000969	CcSEcCtD
Pentoxifylline—Dizziness—Sibutramine—obesity	0.000145	0.000961	CcSEcCtD
Pentoxifylline—Nervousness—Topiramate—obesity	0.000145	0.000961	CcSEcCtD
Pentoxifylline—Back pain—Topiramate—obesity	0.000144	0.000957	CcSEcCtD
Pentoxifylline—Vomiting—Orlistat—obesity	0.000144	0.000955	CcSEcCtD
Pentoxifylline—Muscle spasms—Topiramate—obesity	0.000144	0.000951	CcSEcCtD
Pentoxifylline—Rash—Orlistat—obesity	0.000143	0.000947	CcSEcCtD
Pentoxifylline—Dermatitis—Orlistat—obesity	0.000143	0.000946	CcSEcCtD
Pentoxifylline—Headache—Orlistat—obesity	0.000142	0.000941	CcSEcCtD
Pentoxifylline—Hypersensitivity—Bupropion—obesity	0.000141	0.000933	CcSEcCtD
Pentoxifylline—Vision blurred—Topiramate—obesity	0.000141	0.000932	CcSEcCtD
Pentoxifylline—Tremor—Topiramate—obesity	0.00014	0.000927	CcSEcCtD
Pentoxifylline—Vomiting—Sibutramine—obesity	0.00014	0.000924	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Topiramate—obesity	0.000139	0.000918	CcSEcCtD
Pentoxifylline—Rash—Sibutramine—obesity	0.000138	0.000916	CcSEcCtD
Pentoxifylline—Dermatitis—Sibutramine—obesity	0.000138	0.000915	CcSEcCtD
Pentoxifylline—Anaemia—Topiramate—obesity	0.000138	0.000914	CcSEcCtD
Pentoxifylline—Headache—Sibutramine—obesity	0.000138	0.00091	CcSEcCtD
Pentoxifylline—Asthenia—Bupropion—obesity	0.000137	0.000909	CcSEcCtD
Pentoxifylline—Agitation—Topiramate—obesity	0.000137	0.000909	CcSEcCtD
Pentoxifylline—Pruritus—Bupropion—obesity	0.000135	0.000896	CcSEcCtD
Pentoxifylline—Nausea—Orlistat—obesity	0.000135	0.000892	CcSEcCtD
Pentoxifylline—Malaise—Topiramate—obesity	0.000135	0.000892	CcSEcCtD
Pentoxifylline—Leukopenia—Topiramate—obesity	0.000134	0.000885	CcSEcCtD
Pentoxifylline—Palpitations—Topiramate—obesity	0.000132	0.000874	CcSEcCtD
Pentoxifylline—Diarrhoea—Bupropion—obesity	0.000131	0.000867	CcSEcCtD
Pentoxifylline—Nausea—Sibutramine—obesity	0.00013	0.000863	CcSEcCtD
Pentoxifylline—Convulsion—Topiramate—obesity	0.000129	0.000857	CcSEcCtD
Pentoxifylline—Hypertension—Topiramate—obesity	0.000129	0.000854	CcSEcCtD
Pentoxifylline—Myalgia—Topiramate—obesity	0.000127	0.000842	CcSEcCtD
Pentoxifylline—Chest pain—Topiramate—obesity	0.000127	0.000842	CcSEcCtD
Pentoxifylline—Anxiety—Topiramate—obesity	0.000127	0.000839	CcSEcCtD
Pentoxifylline—Dizziness—Bupropion—obesity	0.000127	0.000838	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	0.000126	0.000836	CcSEcCtD
Pentoxifylline—Discomfort—Topiramate—obesity	0.000126	0.000832	CcSEcCtD
Pentoxifylline—Dry mouth—Topiramate—obesity	0.000124	0.000824	CcSEcCtD
Pentoxifylline—Confusional state—Topiramate—obesity	0.000123	0.000814	CcSEcCtD
Pentoxifylline—Oedema—Topiramate—obesity	0.000122	0.000807	CcSEcCtD
Pentoxifylline—Vomiting—Bupropion—obesity	0.000122	0.000806	CcSEcCtD
Pentoxifylline—Infection—Topiramate—obesity	0.000121	0.000802	CcSEcCtD
Pentoxifylline—Rash—Bupropion—obesity	0.000121	0.000799	CcSEcCtD
Pentoxifylline—Dermatitis—Bupropion—obesity	0.000121	0.000798	CcSEcCtD
Pentoxifylline—Shock—Topiramate—obesity	0.00012	0.000794	CcSEcCtD
Pentoxifylline—Headache—Bupropion—obesity	0.00012	0.000794	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Topiramate—obesity	0.000119	0.00079	CcSEcCtD
Pentoxifylline—Tachycardia—Topiramate—obesity	0.000119	0.000788	CcSEcCtD
Pentoxifylline—Skin disorder—Topiramate—obesity	0.000118	0.000784	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Topiramate—obesity	0.000118	0.00078	CcSEcCtD
Pentoxifylline—Anorexia—Topiramate—obesity	0.000116	0.000769	CcSEcCtD
Pentoxifylline—Hypotension—Topiramate—obesity	0.000114	0.000754	CcSEcCtD
Pentoxifylline—Nausea—Bupropion—obesity	0.000114	0.000753	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Topiramate—obesity	0.000111	0.000735	CcSEcCtD
Pentoxifylline—Insomnia—Topiramate—obesity	0.00011	0.00073	CcSEcCtD
Pentoxifylline—Dyspnoea—Topiramate—obesity	0.000109	0.00072	CcSEcCtD
Pentoxifylline—Somnolence—Topiramate—obesity	0.000108	0.000718	CcSEcCtD
Pentoxifylline—Dyspepsia—Topiramate—obesity	0.000107	0.000711	CcSEcCtD
Pentoxifylline—Decreased appetite—Topiramate—obesity	0.000106	0.000702	CcSEcCtD
Pentoxifylline—Constipation—Topiramate—obesity	0.000104	0.00069	CcSEcCtD
Pentoxifylline—Feeling abnormal—Topiramate—obesity	0.0001	0.000665	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Topiramate—obesity	9.97e-05	0.00066	CcSEcCtD
Pentoxifylline—Urticaria—Topiramate—obesity	9.68e-05	0.000641	CcSEcCtD
Pentoxifylline—Abdominal pain—Topiramate—obesity	9.64e-05	0.000638	CcSEcCtD
Pentoxifylline—Body temperature increased—Topiramate—obesity	9.64e-05	0.000638	CcSEcCtD
Pentoxifylline—Hypersensitivity—Topiramate—obesity	8.98e-05	0.000595	CcSEcCtD
Pentoxifylline—Asthenia—Topiramate—obesity	8.75e-05	0.000579	CcSEcCtD
Pentoxifylline—Pruritus—Topiramate—obesity	8.62e-05	0.000571	CcSEcCtD
Pentoxifylline—Diarrhoea—Topiramate—obesity	8.34e-05	0.000552	CcSEcCtD
Pentoxifylline—Dizziness—Topiramate—obesity	8.06e-05	0.000534	CcSEcCtD
Pentoxifylline—Vomiting—Topiramate—obesity	7.75e-05	0.000513	CcSEcCtD
Pentoxifylline—Rash—Topiramate—obesity	7.69e-05	0.000509	CcSEcCtD
Pentoxifylline—Dermatitis—Topiramate—obesity	7.68e-05	0.000508	CcSEcCtD
Pentoxifylline—Headache—Topiramate—obesity	7.64e-05	0.000506	CcSEcCtD
Pentoxifylline—Nausea—Topiramate—obesity	7.24e-05	0.000479	CcSEcCtD
Pentoxifylline—ADORA2A—Signaling by GPCR—PIK3CB—obesity	7.46e-06	5.56e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PIK3CG—obesity	7.45e-06	5.55e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CCL2—obesity	7.41e-06	5.52e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—TYK2—obesity	7.41e-06	5.52e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—OXCT1—obesity	7.39e-06	5.5e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ACACB—obesity	7.39e-06	5.5e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYTB—obesity	7.39e-06	5.5e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IRS1—obesity	7.36e-06	5.49e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PIK3CG—obesity	7.36e-06	5.48e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—RHOA—obesity	7.35e-06	5.47e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IGF1—obesity	7.28e-06	5.43e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—AKT2—obesity	7.28e-06	5.42e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IRS1—obesity	7.28e-06	5.42e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—NOS3—obesity	7.27e-06	5.42e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—PIK3R1—obesity	7.27e-06	5.42e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PNLIP—obesity	7.2e-06	5.36e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SRD5A1—obesity	7.2e-06	5.36e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—POMC—obesity	7.09e-06	5.28e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—INS—obesity	7.05e-06	5.25e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SDC3—obesity	7.03e-06	5.24e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—POMC—obesity	7.01e-06	5.22e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PRKCD—obesity	7.01e-06	5.22e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—obesity	6.99e-06	5.21e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PIK3CD—obesity	6.99e-06	5.21e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—INS—obesity	6.97e-06	5.19e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CCL2—obesity	6.94e-06	5.17e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—PIK3CA—obesity	6.93e-06	5.16e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—PIK3CA—obesity	6.93e-06	5.16e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—SERPINE1—obesity	6.92e-06	5.15e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—NCOA1—obesity	6.89e-06	5.13e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP26B1—obesity	6.87e-06	5.12e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—STS—obesity	6.87e-06	5.12e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HK2—obesity	6.87e-06	5.12e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CCL2—obesity	6.86e-06	5.11e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—HTR2A—obesity	6.86e-06	5.11e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—C3—obesity	6.85e-06	5.1e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IGF1—obesity	6.82e-06	5.08e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—AKT2—obesity	6.82e-06	5.08e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—obesity	6.79e-06	5.06e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IGF1—obesity	6.74e-06	5.02e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—AKT2—obesity	6.74e-06	5.02e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—TYK2—obesity	6.73e-06	5.01e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PPARD—obesity	6.72e-06	5.01e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MTOR—obesity	6.71e-06	5e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—PIK3CB—obesity	6.71e-06	5e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—RHOA—obesity	6.67e-06	4.97e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PIK3R1—obesity	6.6e-06	4.92e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—NOS3—obesity	6.6e-06	4.92e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SLC27A1—obesity	6.59e-06	4.91e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PIK3CD—obesity	6.55e-06	4.88e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IRS2—obesity	6.51e-06	4.85e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—AGT—obesity	6.5e-06	4.85e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—PIK3CA—obesity	6.49e-06	4.83e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—SERPINE1—obesity	6.48e-06	4.83e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PIK3CD—obesity	6.47e-06	4.82e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GLUL—obesity	6.46e-06	4.81e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—FABP4—obesity	6.46e-06	4.81e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—PIK3CA—obesity	6.41e-06	4.77e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—SERPINE1—obesity	6.4e-06	4.77e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—APOE—obesity	6.37e-06	4.75e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—LEP—obesity	6.37e-06	4.75e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CAV1—obesity	6.31e-06	4.7e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—TYK2—obesity	6.3e-06	4.69e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—APOA1—obesity	6.3e-06	4.69e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—PIK3CA—obesity	6.29e-06	4.69e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—RHOA—obesity	6.25e-06	4.65e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—AKT1—obesity	6.23e-06	4.64e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—TYK2—obesity	6.23e-06	4.64e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PPARGC1A—obesity	6.22e-06	4.64e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—NOS3—obesity	6.18e-06	4.61e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PIK3R1—obesity	6.18e-06	4.61e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—RHOA—obesity	6.17e-06	4.6e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—IL6—obesity	6.13e-06	4.57e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ECHS1—obesity	6.12e-06	4.56e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—UCP2—obesity	6.12e-06	4.56e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—UCP3—obesity	6.12e-06	4.56e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HSD11B1—obesity	6.12e-06	4.56e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PIK3R1—obesity	6.11e-06	4.55e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—NOS3—obesity	6.11e-06	4.55e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PIK3CB—obesity	6.1e-06	4.54e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MTOR—obesity	6.1e-06	4.54e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—ESR1—obesity	6.09e-06	4.53e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ADH1B—obesity	6.02e-06	4.49e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PRKCB—obesity	6.01e-06	4.48e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—F2—obesity	6.01e-06	4.48e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—BAD—obesity	5.94e-06	4.42e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—APOB—obesity	5.93e-06	4.42e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PPARGC1B—obesity	5.93e-06	4.42e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GPAM—obesity	5.93e-06	4.42e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ACSL1—obesity	5.93e-06	4.42e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—PIK3CA—obesity	5.89e-06	4.39e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MMP9—obesity	5.84e-06	4.35e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—PIK3CA—obesity	5.82e-06	4.34e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HADH—obesity	5.76e-06	4.29e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PCK1—obesity	5.76e-06	4.29e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—FADS1—obesity	5.76e-06	4.29e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PIK3CG—obesity	5.75e-06	4.28e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MTOR—obesity	5.71e-06	4.25e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PIK3CB—obesity	5.71e-06	4.25e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IRS1—obesity	5.69e-06	4.24e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MAPK8—obesity	5.68e-06	4.23e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—LPL—obesity	5.67e-06	4.22e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—AKT1—obesity	5.66e-06	4.22e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—AKT1—obesity	5.66e-06	4.22e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MTOR—obesity	5.64e-06	4.2e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PIK3CB—obesity	5.64e-06	4.2e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ACP5—obesity	5.6e-06	4.17e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—IL6—obesity	5.57e-06	4.15e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—obesity	5.53e-06	4.12e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—POMC—obesity	5.48e-06	4.08e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—G6PD—obesity	5.46e-06	4.06e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—INS—obesity	5.44e-06	4.06e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SREBF2—obesity	5.39e-06	4.02e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HK1—obesity	5.39e-06	4.02e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—CD36—obesity	5.38e-06	4.01e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CCL2—obesity	5.36e-06	3.99e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—AKT1—obesity	5.3e-06	3.95e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MMP9—obesity	5.3e-06	3.95e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IGF1—obesity	5.27e-06	3.92e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—AKT2—obesity	5.26e-06	3.92e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—AKT1—obesity	5.24e-06	3.9e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—IL6—obesity	5.22e-06	3.89e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—LPA—obesity	5.21e-06	3.88e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—STAT3—obesity	5.19e-06	3.86e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—IL6—obesity	5.15e-06	3.84e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MAPK8—obesity	5.15e-06	3.84e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—AKT1—obesity	5.14e-06	3.83e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—LPIN1—obesity	5.09e-06	3.79e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PIK3CD—obesity	5.06e-06	3.77e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—PIK3CA—obesity	5.01e-06	3.73e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—obesity	5.01e-06	3.73e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—SERPINE1—obesity	5e-06	3.73e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—APOA5—obesity	4.99e-06	3.72e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MMP9—obesity	4.96e-06	3.7e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MMP9—obesity	4.9e-06	3.65e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—TYK2—obesity	4.86e-06	3.62e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—AGT—obesity	4.85e-06	3.61e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MAPK8—obesity	4.83e-06	3.59e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—RHOA—obesity	4.82e-06	3.59e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MYC—obesity	4.82e-06	3.59e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—AKT1—obesity	4.81e-06	3.58e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—TGFB1—obesity	4.81e-06	3.58e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PIK3R1—obesity	4.77e-06	3.56e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—NOS3—obesity	4.77e-06	3.56e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MAPK8—obesity	4.77e-06	3.55e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CLOCK—obesity	4.76e-06	3.55e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SLC22A1—obesity	4.76e-06	3.55e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—AKT1—obesity	4.76e-06	3.54e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—APOE—obesity	4.75e-06	3.54e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—STAT3—obesity	4.71e-06	3.51e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—obesity	4.71e-06	3.51e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—obesity	4.7e-06	3.5e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SULT2A1—obesity	4.64e-06	3.46e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GLP1R—obesity	4.64e-06	3.46e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—DPYD—obesity	4.56e-06	3.4e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—PIK3CA—obesity	4.55e-06	3.39e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—STAT3—obesity	4.41e-06	3.29e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MTOR—obesity	4.41e-06	3.28e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PIK3CB—obesity	4.41e-06	3.28e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PRKAR2B—obesity	4.39e-06	3.27e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MYC—obesity	4.38e-06	3.26e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—TGFB1—obesity	4.37e-06	3.25e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—DCN—obesity	4.36e-06	3.25e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—STAT3—obesity	4.36e-06	3.25e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—obesity	4.29e-06	3.19e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CPT1A—obesity	4.24e-06	3.16e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NAMPT—obesity	4.16e-06	3.1e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—obesity	4.14e-06	3.08e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—LIPC—obesity	4.14e-06	3.08e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GCK—obesity	4.14e-06	3.08e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—APOC3—obesity	4.11e-06	3.06e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MYC—obesity	4.1e-06	3.05e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—PIK3CA—obesity	4.09e-06	3.05e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—AKT1—obesity	4.09e-06	3.05e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—TGFB1—obesity	4.09e-06	3.05e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—POMC—obesity	4.08e-06	3.04e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MYC—obesity	4.05e-06	3.02e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—TGFB1—obesity	4.04e-06	3.01e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—IL6—obesity	4.03e-06	3e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CETP—obesity	3.99e-06	2.97e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SDC1—obesity	3.95e-06	2.94e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—AKR1C3—obesity	3.88e-06	2.89e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MMP9—obesity	3.83e-06	2.85e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SCARB1—obesity	3.82e-06	2.85e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—obesity	3.77e-06	2.81e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MAPK8—obesity	3.73e-06	2.78e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—ALB—obesity	3.72e-06	2.77e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PIK3CA—obesity	3.72e-06	2.77e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—AKT1—obesity	3.72e-06	2.77e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SREBF1—obesity	3.71e-06	2.76e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—IL6—obesity	3.62e-06	2.7e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GOT2—obesity	3.61e-06	2.69e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—obesity	3.56e-06	2.65e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—FASN—obesity	3.53e-06	2.63e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—BCHE—obesity	3.52e-06	2.62e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PIK3CA—obesity	3.48e-06	2.59e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PIK3CA—obesity	3.44e-06	2.56e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—STAT3—obesity	3.41e-06	2.54e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP2E1—obesity	3.39e-06	2.53e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NQO1—obesity	3.35e-06	2.5e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—AKT1—obesity	3.34e-06	2.49e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IL6—obesity	3.29e-06	2.45e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—obesity	3.28e-06	2.45e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—obesity	3.25e-06	2.42e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GCG—obesity	3.22e-06	2.4e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SLC2A4—obesity	3.22e-06	2.4e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYCS—obesity	3.17e-06	2.36e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MYC—obesity	3.17e-06	2.36e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—TGFB1—obesity	3.16e-06	2.35e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GGT1—obesity	3.11e-06	2.32e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GOT1—obesity	3.11e-06	2.32e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IL6—obesity	3.08e-06	2.3e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NCOA1—obesity	3.07e-06	2.29e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IL6—obesity	3.04e-06	2.27e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—AKT1—obesity	3.04e-06	2.26e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—STK11—obesity	3.02e-06	2.25e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP19A1—obesity	3.02e-06	2.25e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—AKT1—obesity	2.84e-06	2.12e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—COMT—obesity	2.81e-06	2.09e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—AKT1—obesity	2.81e-06	2.09e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GNB3—obesity	2.77e-06	2.06e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PPARGC1A—obesity	2.77e-06	2.06e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HMOX1—obesity	2.76e-06	2.06e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GNAS—obesity	2.7e-06	2.01e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PIK3CA—obesity	2.69e-06	2e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—APOB—obesity	2.64e-06	1.97e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—LPL—obesity	2.52e-06	1.88e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GPX1—obesity	2.46e-06	1.83e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CD36—obesity	2.4e-06	1.79e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IL6—obesity	2.38e-06	1.77e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—MTHFR—obesity	2.27e-06	1.69e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PPARA—obesity	2.23e-06	1.66e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—AKT1—obesity	2.19e-06	1.63e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—AGT—obesity	2.16e-06	1.61e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—APOE—obesity	2.12e-06	1.58e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CAV1—obesity	2.1e-06	1.56e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—APOA1—obesity	2.09e-06	1.56e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—obesity	2e-06	1.49e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PIK3CG—obesity	1.91e-06	1.42e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PPARG—obesity	1.84e-06	1.37e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—POMC—obesity	1.82e-06	1.35e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—INS—obesity	1.81e-06	1.35e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PIK3CD—obesity	1.68e-06	1.25e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ALB—obesity	1.66e-06	1.23e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NOS3—obesity	1.58e-06	1.18e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PIK3R1—obesity	1.58e-06	1.18e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PIK3CB—obesity	1.46e-06	1.09e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PTGS2—obesity	1.45e-06	1.08e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PIK3CA—obesity	8.92e-07	6.64e-06	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—AKT1—obesity	7.29e-07	5.43e-06	CbGpPWpGaD
